Maria N. Navarro
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Maria N. Navarro has a total of 93 co-authors. Here are the top co-authors by number of shared publications:
- Doreen Ann Cantrell
Division of Cell Signalling and Immunology, School of Life Sciences, University of Dundee, Dundee, UK
8 shared publications Carmen Feijoo-Carnero
Division of Cell Signalling and Immunology, College of Life Sciences, University of Dundee, Dundee DD1 5EH, UK
4 shared publications- Maria Luisa Toribio
Centro de Biología Molecular Severo Ochoa CSIC-UAM, Madrid, Spain
4 shared publications - Sharon A. Matthews
Medical Research Institute, Ninewells Hospital and Medical School University of Dundee, Dundee, UK
3 shared publications Aurea Oliva
Universidad Autónoma de Madrid
2 shared publicationsBalbino Alarcón
Interactions with the Environment Program, Centro Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas, Universidad Autónoma de Madrid, Madrid, Spain
2 shared publications
Latest Publications
- Open Access
Nicotinamide Riboside Attenuates inflammation in a mouse model of psoriasis
Psoriasis is a chronic inflammatory skin disease driven by dysregulated immune responses, in which IL–17–producing T cells play a central role. Nicotinamide riboside (NR), a precursor of NAD+, has recently emerged as a potential immunomodulatory intervention. Previous studies have shown that NR preferentially suppresses Th17 responsiveness in CD4+ T cells from individuals with psoriasis, but whether NR can attenuate psoriasiform inflammation in vivo remains poorly defined. Here, we investigated the effects of NR supplementation in a mouse model of imiquimod (IMQ)–induced psoriasiform skin inflammation. NR treatment markedly attenuated IMQ–induced splenomegaly and reduced epidermal thickening, indicating an improvement of both systemic and cutaneous inflammatory manifestations. Flow cytometric analysis of skin infiltrates revealed a reduction in inflammatory myeloid populations, including neutrophils and inflammatory monocyte–macrophages, together with a pronounced decrease in dermal TCR γδ and CD4+ T cells. Consistent with these findings, CD4+ T cells isolated from IMQ-treated mice displayed increased IL–17A production following ex vivo TCR stimulation, which was significantly reduced by NR supplementation in a dose-dependent manner. IFNγ and IL–4 responses were not significantly altered by NR in this setting. Furthermore, NR suppressed IL–17A production in Th17–polarized CD4+ T cells, while leaving Th1 and Th2 responses largely unaffected. Together, these findings show that NR treatment attenuates IMQ-induced psoriasiform skin inflammation in vivo and preferentially modulates IL–17A–associated CD4⁺ T–cell responses. The accompanying reduction in dermal γδ T–cell numbers suggests that NR may also influence innate-like T–cell populations involved in cutaneous inflammation, providing experimental evidence for NAD+ boosting as a potential immunomodulatory strategy in psoriasis.
Open AccessNicotinamide Riboside Attenuates inflammation in a mouse model of psoriasis
Psoriasis is a chronic inflammatory skin disease driven by dysregulated immune responses, in which IL–17–producing T cells play a central role. Nicotinamide riboside (NR), a precursor of NAD+, has recently emerged as a potential immunomodulatory intervention. Previous studies have shown that NR preferentially suppresses Th17 responsiveness in CD4+ T cells from individuals with psoriasis, but whether NR can attenuate psoriasiform inflammation in vivo remains poorly defined. Here, we investigated the effects of NR supplementation in a mouse model of imiquimod (IMQ)–induced psoriasiform skin inflammation. NR treatment markedly attenuated IMQ–induced splenomegaly and reduced epidermal thickening, indicating an improvement of both systemic and cutaneous inflammatory manifestations. Flow cytometric analysis of skin infiltrates revealed a reduction in inflammatory myeloid populations, including neutrophils and inflammatory monocyte–macrophages, together with a pronounced decrease in dermal TCR γδ and CD4+ T cells. Consistent with these findings, CD4+ T cells isolated from IMQ-treated mice displayed increased IL–17A production following ex vivo TCR stimulation, which was significantly reduced by NR supplementation in a dose-dependent manner. IFNγ and IL–4 responses were not significantly altered by NR in this setting. Furthermore, NR suppressed IL–17A production in Th17–polarized CD4+ T cells, while leaving Th1 and Th2 responses largely unaffected. Together, these findings show that NR treatment attenuates IMQ-induced psoriasiform skin inflammation in vivo and preferentially modulates IL–17A–associated CD4⁺ T–cell responses. The accompanying reduction in dermal γδ T–cell numbers suggests that NR may also influence innate-like T–cell populations involved in cutaneous inflammation, providing experimental evidence for NAD+ boosting as a potential immunomodulatory strategy in psoriasis.
- Open Access
- 9 March 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 158 (1) , 164-181
Drug screening identifies Src/Abl inhibitor dasatinib as suppressor of IL-23 signaling in skin inflammation
- 9 March 2026
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 158 (1) , 164-181
Open AccessDrug screening identifies Src/Abl inhibitor dasatinib as suppressor of IL-23 signaling in skin inflammation
- Open Access
- 31 March 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 799919
Mutation of the Polyproline Sequence in CD3ε Evidences TCR Signaling Requirements for Differentiation and Function of Pro-Inflammatory Tγδ17 Cells
Tγδ17 cells have emerged as a key population in the development of inflammatory and autoimmune conditions such as psoriasis. Thus, the therapeutic intervention of Tγδ17 cells can exert protective effects in this type of pathologies. Tγδ cells commit to IL-17 production during thymus development, and upon immune challenge, additional extrathymic signals induce the differentiation of uncommitted Tγδ cells into Tγδ17 effector cells. Despite the interest in Tγδ17 cells during the past 20 years, the role of TCR signaling in the generation and function of Tγδ17 cells has not been completely elucidated. While some studies point to the notion that Tγδ17 differentiation requires weak or no TCR signaling, other works suggest that Tγδ17 require the participation of specific kinases and adaptor molecules downstream of the TCR. Here we have examined the differentiation and pathogenic function of Tγδ17 cells in “knockin” mice bearing conservative mutations in the CD3ε polyproline rich sequence (KI-PRS) with attenuated TCR signaling due to lack of binding of the essential adaptor Nck. KI-PRS mice presented decreased frequency and numbers of Tγδ17 cells in adult thymus and lymph nodes. In the Imiquimod model of skin inflammation, KI-PRS presented attenuated skin inflammation parameters compared to wild-type littermates. Moreover, the generation, expansion and effector function Tγδ17 cells were impaired in KI-PRS mice upon Imiquimod challenge. Thus, we conclude that an intact CD3ε-PRS sequence is required for optimal differentiation and pathogenic function of Tγδ17 cells. These data open new opportunities for therapeutic targeting of specific TCR downstream effectors for treatment of Tγδ17-mediated diseases.
- 31 March 2022
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 799919
Open AccessMutation of the Polyproline Sequence in CD3ε Evidences TCR Signaling Requirements for Differentiation and Function of Pro-Inflammatory Tγδ17 Cells
Tγδ17 cells have emerged as a key population in the development of inflammatory and autoimmune conditions such as psoriasis. Thus, the therapeutic intervention of Tγδ17 cells can exert protective effects in this type of pathologies. Tγδ cells commit to IL-17 production during thymus development, and upon immune challenge, additional extrathymic signals induce the differentiation of uncommitted Tγδ cells into Tγδ17 effector cells. Despite the interest in Tγδ17 cells during the past 20 years, the role of TCR signaling in the generation and function of Tγδ17 cells has not been completely elucidated. While some studies point to the notion that Tγδ17 differentiation requires weak or no TCR signaling, other works suggest that Tγδ17 require the participation of specific kinases and adaptor molecules downstream of the TCR. Here we have examined the differentiation and pathogenic function of Tγδ17 cells in “knockin” mice bearing conservative mutations in the CD3ε polyproline rich sequence (KI-PRS) with attenuated TCR signaling due to lack of binding of the essential adaptor Nck. KI-PRS mice presented decreased frequency and numbers of Tγδ17 cells in adult thymus and lymph nodes. In the Imiquimod model of skin inflammation, KI-PRS presented attenuated skin inflammation parameters compared to wild-type littermates. Moreover, the generation, expansion and effector function Tγδ17 cells were impaired in KI-PRS mice upon Imiquimod challenge. Thus, we conclude that an intact CD3ε-PRS sequence is required for optimal differentiation and pathogenic function of Tγδ17 cells. These data open new opportunities for therapeutic targeting of specific TCR downstream effectors for treatment of Tγδ17-mediated diseases.
- Open Access
- 1 June 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (6) , 1522-1532.e3
Galectin-1 Expression in CD8+ T Lymphocytes Controls Inflammation in Contact Hypersensitivity
- 1 June 2021
- Published by Elsevier in Journal of Investigative Dermatology
- Vol. 141 (6) , 1522-1532.e3
Open AccessGalectin-1 Expression in CD8+ T Lymphocytes Controls Inflammation in Contact Hypersensitivity
- Open Access
- 12 May 2021
- Published by Wiley in British Journal of Pharmacology
- Vol. 179 (9) , 1839-1856
Nicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing
Metabolism is dynamically regulated to accompany immune cell function, and altered immunometabolism can result in impaired immune responses. Concomitantly, the pharmacological manipulation of metabolic processes offers an opportunity for therapeutic intervention in inflammatory disorders. The nicotinamide adenine dinucleotide (NAD+) is a critical metabolic intermediate that serves as enzyme cofactor in redox reactions, and is also used as a co‐substrate by many enzymes such as sirtuins, adenosine diphosphate ribose transferases and synthases. Through these activities, NAD+ metabolism regulates a broad spectrum of cellular functions such as energy metabolism, DNA repair, regulation of the epigenetic landscape and inflammation. Thus, the manipulation of NAD+ availability using pharmacological compounds such as NAD+ precursors can have immune‐modulatory properties in inflammation. Here, we discuss how the NAD+ metabolism contributes to the immune response and inflammatory conditions, with a special focus on multiple sclerosis, inflammatory bowel diseases and inflammageing.LINKED ARTICLES: This article is part of a themed issue on Inflammation, Repair and Ageing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.9/issuetoc
- 12 May 2021
- Published by Wiley in British Journal of Pharmacology
- Vol. 179 (9) , 1839-1856
Open AccessNicotinamide adenine dinucleotide metabolism in the immune response, autoimmunity and inflammageing
Metabolism is dynamically regulated to accompany immune cell function, and altered immunometabolism can result in impaired immune responses. Concomitantly, the pharmacological manipulation of metabolic processes offers an opportunity for therapeutic intervention in inflammatory disorders. The nicotinamide adenine dinucleotide (NAD+) is a critical metabolic intermediate that serves as enzyme cofactor in redox reactions, and is also used as a co‐substrate by many enzymes such as sirtuins, adenosine diphosphate ribose transferases and synthases. Through these activities, NAD+ metabolism regulates a broad spectrum of cellular functions such as energy metabolism, DNA repair, regulation of the epigenetic landscape and inflammation. Thus, the manipulation of NAD+ availability using pharmacological compounds such as NAD+ precursors can have immune‐modulatory properties in inflammation. Here, we discuss how the NAD+ metabolism contributes to the immune response and inflammatory conditions, with a special focus on multiple sclerosis, inflammatory bowel diseases and inflammageing.LINKED ARTICLES: This article is part of a themed issue on Inflammation, Repair and Ageing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.9/issuetoc
- Open Access
Decoding IL-23 Signaling Cascade for New Therapeutic Opportunities
The interleukin 23 (IL-23) is a key pro-inflammatory cytokine in the development of chronic inflammatory diseases, such as psoriasis, inflammatory bowel diseases, multiple sclerosis, or rheumatoid arthritis. The pathological consequences of excessive IL-23 signaling have been linked to its ability to promote the production of inflammatory mediators, such as IL-17, IL-22, granulocyte-macrophage colony-stimulating (GM-CSF), or the tumor necrosis factor (TNFα) by target populations, mainly Th17 and IL-17-secreting TCRγδ cells (Tγδ17). Due to their pivotal role in inflammatory diseases, IL-23 and its downstream effector molecules have emerged as attractive therapeutic targets, leading to the development of neutralizing antibodies against IL-23 and IL-17 that have shown efficacy in different inflammatory diseases. Despite the success of monoclonal antibodies, there are patients that show no response or partial response to these treatments. Thus, effective therapies for inflammatory diseases may require the combination of multiple immune-modulatory drugs to prevent disease progression and to improve quality of life. Alternative strategies aimed at inhibiting intracellular signaling cascades using small molecule inhibitors or interfering peptides have not been fully exploited in the context of IL-23-mediated diseases. In this review, we discuss the current knowledge about proximal signaling events triggered by IL-23 upon binding to its membrane receptor to bring to the spotlight new opportunities for therapeutic intervention in IL-23-mediated pathologies.
Open AccessDecoding IL-23 Signaling Cascade for New Therapeutic Opportunities
The interleukin 23 (IL-23) is a key pro-inflammatory cytokine in the development of chronic inflammatory diseases, such as psoriasis, inflammatory bowel diseases, multiple sclerosis, or rheumatoid arthritis. The pathological consequences of excessive IL-23 signaling have been linked to its ability to promote the production of inflammatory mediators, such as IL-17, IL-22, granulocyte-macrophage colony-stimulating (GM-CSF), or the tumor necrosis factor (TNFα) by target populations, mainly Th17 and IL-17-secreting TCRγδ cells (Tγδ17). Due to their pivotal role in inflammatory diseases, IL-23 and its downstream effector molecules have emerged as attractive therapeutic targets, leading to the development of neutralizing antibodies against IL-23 and IL-17 that have shown efficacy in different inflammatory diseases. Despite the success of monoclonal antibodies, there are patients that show no response or partial response to these treatments. Thus, effective therapies for inflammatory diseases may require the combination of multiple immune-modulatory drugs to prevent disease progression and to improve quality of life. Alternative strategies aimed at inhibiting intracellular signaling cascades using small molecule inhibitors or interfering peptides have not been fully exploited in the context of IL-23-mediated diseases. In this review, we discuss the current knowledge about proximal signaling events triggered by IL-23 upon binding to its membrane receptor to bring to the spotlight new opportunities for therapeutic intervention in IL-23-mediated pathologies.
- Top Cited Papers
- 19 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 368 (6497) , 1371-1376
T cells with dysfunctional mitochondria induce multimorbidity and premature senescence
Inflammaging? Blame T cells!: Mitochondrial dysfunction in various tissues is a prominent characteristic of age-related deterioration, but it is unclear how mitochondrial dysfunction in particular cell types contributes to this process. Desdín-Micó et al. generated mice with T cells that were specifically deficient in a mitochondrial DNA–stabilizing protein. These animals exhibited multiple features associated with aging, including neurological, metabolic, muscular, and cardiovascular impairments. The defective T cells initiated an inflammatory program similar to that observed in older animals, a process called “inflammaging.” Blocking the cytokine tumor necrosis factor–α or administering precursors of the cofactor nicotinamide adenine dinucleotide restored many of these symptoms of senescence. These findings may potentially inform future therapies for age-associated diseases, as well as cachexia and cytokine-release syndrome. Science , this issue p. 1371
- 19 June 2020
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 368 (6497) , 1371-1376
Top Cited PapersT cells with dysfunctional mitochondria induce multimorbidity and premature senescence
Inflammaging? Blame T cells!: Mitochondrial dysfunction in various tissues is a prominent characteristic of age-related deterioration, but it is unclear how mitochondrial dysfunction in particular cell types contributes to this process. Desdín-Micó et al. generated mice with T cells that were specifically deficient in a mitochondrial DNA–stabilizing protein. These animals exhibited multiple features associated with aging, including neurological, metabolic, muscular, and cardiovascular impairments. The defective T cells initiated an inflammatory program similar to that observed in older animals, a process called “inflammaging.” Blocking the cytokine tumor necrosis factor–α or administering precursors of the cofactor nicotinamide adenine dinucleotide restored many of these symptoms of senescence. These findings may potentially inform future therapies for age-associated diseases, as well as cachexia and cytokine-release syndrome. Science , this issue p. 1371
- Open Access
- 23 March 2020
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 18 (3) , e3000646
IL-23 signaling regulation of pro-inflammatory T-cell migration uncovered by phosphoproteomics
Interleukin 23 (IL-23) triggers pathogenic features in pro-inflammatory, IL-17-secreting T cells (Th17 and Tγδ17) that play a key role in the development of inflammatory diseases. However, the IL-23 signaling cascade remains largely undefined. Here, we used quantitative phosphoproteomics to characterize IL-23 signaling in primary murine Th17 cells. We quantified 6,888 phosphorylation sites in Th17 cells and found 168 phosphorylations regulated upon IL-23 stimulation. IL-23 increased the phosphorylation of the myosin regulatory light chain (RLC), an actomyosin contractibility marker, in Th17 and Tγδ17 cells. IL-23-induced RLC phosphorylation required Janus kinase 2 (JAK2) and Rho-associated protein kinase (ROCK) catalytic activity, and further study of the IL-23/ROCK connection revealed an unexpected role of IL-23 in the migration of Tγδ17 and Th17 cells through ROCK activation. In addition, pharmacological inhibition of ROCK reduced Tγδ17 recruitment to inflamed skin upon challenge with inflammatory agent Imiquimod. This work (i) provides new insights into phosphorylation networks that control Th17 cells, (ii) widely expands the current knowledge on IL-23 signaling, and (iii) contributes to the increasing list of immune cells subsets characterized by global phosphoproteomic approaches.
- 23 March 2020
- Published by Public Library of Science (PLoS) in PLOS Biology
- Vol. 18 (3) , e3000646
Open AccessIL-23 signaling regulation of pro-inflammatory T-cell migration uncovered by phosphoproteomics
Interleukin 23 (IL-23) triggers pathogenic features in pro-inflammatory, IL-17-secreting T cells (Th17 and Tγδ17) that play a key role in the development of inflammatory diseases. However, the IL-23 signaling cascade remains largely undefined. Here, we used quantitative phosphoproteomics to characterize IL-23 signaling in primary murine Th17 cells. We quantified 6,888 phosphorylation sites in Th17 cells and found 168 phosphorylations regulated upon IL-23 stimulation. IL-23 increased the phosphorylation of the myosin regulatory light chain (RLC), an actomyosin contractibility marker, in Th17 and Tγδ17 cells. IL-23-induced RLC phosphorylation required Janus kinase 2 (JAK2) and Rho-associated protein kinase (ROCK) catalytic activity, and further study of the IL-23/ROCK connection revealed an unexpected role of IL-23 in the migration of Tγδ17 and Th17 cells through ROCK activation. In addition, pharmacological inhibition of ROCK reduced Tγδ17 recruitment to inflamed skin upon challenge with inflammatory agent Imiquimod. This work (i) provides new insights into phosphorylation networks that control Th17 cells, (ii) widely expands the current knowledge on IL-23 signaling, and (iii) contributes to the increasing list of immune cells subsets characterized by global phosphoproteomic approaches.
- Open Access
- 9 August 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 938
Lighting Up T Lymphocyte Signaling with Quantitative Phosphoproteomics
Phosphorylation is the most abundant post-translational modification, regulating several aspects of protein and cell function. Quantitative phosphoproteomics approaches have expanded the scope of phosphorylation analysis enabling the quantification of changes in thousands of phosphorylation sites simultaneously in two or more conditions. These approaches offer a global view of the impact of cellular perturbations such as extracellular stimuli or gene ablation in intracellular signaling networks. Such great potential also brings on a new challenge: to identify, among the thousands of phosphorylations found in global phosphoproteomics studies, the small subset of site-specific phosphorylations expected to be functionally relevant. This review focus on updating and integrating findings on T lymphocyte signaling generated using global phosphoproteomics approaches, drawing attention on the biological relevance of the obtained data.
- 9 August 2017
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 8, 938
Open AccessLighting Up T Lymphocyte Signaling with Quantitative Phosphoproteomics
Phosphorylation is the most abundant post-translational modification, regulating several aspects of protein and cell function. Quantitative phosphoproteomics approaches have expanded the scope of phosphorylation analysis enabling the quantification of changes in thousands of phosphorylation sites simultaneously in two or more conditions. These approaches offer a global view of the impact of cellular perturbations such as extracellular stimuli or gene ablation in intracellular signaling networks. Such great potential also brings on a new challenge: to identify, among the thousands of phosphorylations found in global phosphoproteomics studies, the small subset of site-specific phosphorylations expected to be functionally relevant. This review focus on updating and integrating findings on T lymphocyte signaling generated using global phosphoproteomics approaches, drawing attention on the biological relevance of the obtained data.
- Open Access
- 30 May 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 15620
Glucose represses dendritic cell-induced T cell responses
Glucose and glycolysis are important for the proinflammatory functions of many immune cells, and depletion of glucose in pathological microenvironments is associated with defective immune responses. Here we show a contrasting function for glucose in dendritic cells (DCs), as glucose represses the proinflammatory output of LPS-stimulated DCs and inhibits DC-induced T-cell responses. A glucose-sensitive signal transduction circuit involving the mTOR complex 1 (mTORC1), HIF1α and inducible nitric oxide synthase (iNOS) coordinates DC metabolism and function to limit DC-stimulated T-cell responses. When multiple T cells interact with a DC, they compete for nutrients, which can limit glucose availability to the DCs. In such DCs, glucose-dependent signalling is inhibited, altering DC outputs and enhancing T-cell responses. These data reveal a mechanism by which T cells regulate the DC microenvironment to control DC-induced T-cell responses and indicate that glucose is an important signal for shaping immune responses.
- 30 May 2017
- Published by Springer Nature in Nature Communications
- Vol. 8 (1) , 15620
Open AccessGlucose represses dendritic cell-induced T cell responses
Glucose and glycolysis are important for the proinflammatory functions of many immune cells, and depletion of glucose in pathological microenvironments is associated with defective immune responses. Here we show a contrasting function for glucose in dendritic cells (DCs), as glucose represses the proinflammatory output of LPS-stimulated DCs and inhibits DC-induced T-cell responses. A glucose-sensitive signal transduction circuit involving the mTOR complex 1 (mTORC1), HIF1α and inducible nitric oxide synthase (iNOS) coordinates DC metabolism and function to limit DC-stimulated T-cell responses. When multiple T cells interact with a DC, they compete for nutrients, which can limit glucose availability to the DCs. In such DCs, glucose-dependent signalling is inhibited, altering DC outputs and enhancing T-cell responses. These data reveal a mechanism by which T cells regulate the DC microenvironment to control DC-induced T-cell responses and indicate that glucose is an important signal for shaping immune responses.